Arthritis Research & Therapy | 2019

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

 
 
 
 
 
 
 
 
 
 
 

Abstract


BackgroundTumor necrosis factor (TNF) inhibitors (TNF-i) are effective in the treatment of entero-Behcet’s disease (BD). However, there is no objective tool for assessment of disease activity in entero-BD; therefore, it is not easy to evaluate treatment effectiveness in the clinical setting. In addition, because corticosteroid (CS) is considered for standard therapy, the effectiveness of TNF-i without CS has not been well examined. In this retrospective study, the effectiveness of CS without TNF-i and the effectiveness of TNF-i with or without CS therapy were investigated and compared.MethodsThis study included 71 patients with entero-BD who were followed up for 1\u2009year (CS without TNF-i group: n\u2009=\u200922; TNF-i group: n\u2009=\u200949 [with CS: n\u2009=\u200920, without CS: n\u2009=\u200929]). All patients had active ulcerative lesions. The primary endpoint was the ulcer cure rate evaluated by lower gastrointestinal endoscopy. Secondary endpoints were ulcer improvement rate, disease activity improvement based on the quantitative disease activity index for intestinal Behcet’s disease (DAIBD), and CS-sparing effect.ResultsUlcer cure rates were 13.6% in the CS without TNF-i group, 60.0% in the TNF-i with CS group, and 44.8% in the TNF-i without CS group. Ulcer improvement rates were 27.2% in the CS without TNF-i group, 60.0% in the TNF-i with CS group, and 51.7% in the TNF-i without CS group. The multivariate analysis revealed that TNF-i was an independent predictive factor for cure of the ulcerative lesions. The DAIBD and concomitant CS dose were significantly decreased in both the CS without TNF-i group (DAIBD 85.2\u2009→\u200940.5, CS 32.3\u2009→\u200918.7\u2009mg/day) and the TNF-i group (DAIBD 64.7\u2009→\u200921.1. CS 18.7\u2009→\u20093.88\u2009mg/day). The ulcer cure and improvement rates were significantly higher in the TNF-i group. In addition, the proportion of concomitant CS dose less than 7.5\u2009mg was significantly higher in the TNF-i group (CS without TNF-i group 18.2% vs. TNF-i group 85%, P\u2009<\u20090.01). There were no statistically significant differences between the TNF-i with CS group and the TNF-i without CS group in any of the endpoints.ConclusionsThis study demonstrated that compared to CS alone, TNF-i improve disease activity and possess a higher ulcer healing effect and CS tapering effect with or without concomitant CS.

Volume 21
Pages None
DOI 10.1186/s13075-019-1933-8
Language English
Journal Arthritis Research & Therapy

Full Text